Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.725 GBX | -1.97% | +2.05% | -12.35% |
May. 23 | Celadon ships to US; Oxford BioDynamics-Goodbody pact | AN |
May. 23 | Fusion Antibodies plc Announces New Contract with Existing Client Project to Develop Therapeutic | CI |
Valuation
Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Capitalization 1 | 6.296 | 20.99 | 40.21 | 15.61 | 10.02 | 3.624 |
Enterprise Value (EV) 1 | 6.296 | 19.83 | 40.21 | 15.61 | 10.02 | 3.624 |
P/E ratio | -5 x | -29.7 x | -13.8 x | -13 x | -3.85 x | -1.23 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 2.89 x | 5.39 x | - | - | 3.45 x | 3.18 x |
EV / Revenue | 2.89 x | 5.39 x | - | - | 3.45 x | 3.18 x |
EV / EBITDA | -5.72 x | -47.8 x | - | - | -4.03 x | -2.25 x |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 22,091 | 22,091 | 25,610 | 26,015 | 26,015 | 95,366 |
Reference price 2 | 0.2850 | 0.9500 | 1.570 | 0.6000 | 0.3850 | 0.0380 |
Announcement Date | 7/2/19 | 8/19/20 | 8/10/21 | 8/23/22 | 9/29/23 | - |
Income Statement Evolution (Annual data)
Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Net sales 1 | 2.182 | 3.895 | - | - | 2.901 | 1.14 |
EBITDA 1 | -1.1 | -0.439 | - | - | -2.486 | -1.614 |
EBIT 1 | - | -1.059 | - | - | -2.858 | -1.864 |
Operating Margin | - | -27.19% | - | - | -98.52% | -163.51% |
Earnings before Tax (EBT) 1 | - | -1.073 | - | - | -2.859 | -1.876 |
Net income 1 | - | -0.697 | -2.899 | -1.2 | -2.596 | -1.73 |
Net margin | - | -17.89% | - | - | -89.49% | -151.75% |
EPS 2 | -0.0570 | -0.0320 | -0.1140 | -0.0460 | -0.1000 | -0.0310 |
Free Cash Flow | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 7/2/19 | 8/19/20 | 8/10/21 | 8/23/22 | 9/29/23 | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: March | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
---|---|---|---|---|
Net sales 1 | - | 1.038 | 0.541 | 0.599 |
EBITDA 1 | - | -1.478 | -1.231 | -0.541 |
EBIT | - | - | - | - |
Operating Margin | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -1.597 | -1.42 | -0.672 |
Net income | -1.116 | - | - | - |
Net margin | - | - | - | - |
EPS | -0.0430 | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 12/5/22 | 9/29/23 | 12/4/23 | - |
Balance Sheet Analysis
Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - |
Net Cash position | - | 1.16 | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex 1 | 1.37 | - | - | - | 0.11 | 0.05 |
Capex / Sales | 62.91% | - | - | - | 3.93% | 4.39% |
Announcement Date | 7/2/19 | 8/19/20 | 8/10/21 | 8/23/22 | 9/29/23 | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.35% | 4.61M | |
+46.06% | 56.69B | |
-2.93% | 41B | |
+38.14% | 38.11B | |
-11.22% | 26.89B | |
+15.82% | 25.59B | |
-22.28% | 18.59B | |
-0.11% | 12.39B | |
+26.01% | 11.99B | |
+22.85% | 11.88B |
- Stock Market
- Equities
- FAB Stock
- Financials Fusion Antibodies plc